Viking Therapeutics to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Viking Therapeutics (NASDAQ: VKTX) has announced its participation in two major upcoming investor conferences in March 2025. The company will attend the Leerink Partners Global Healthcare Conference 2025 from March 10-12, where management will engage in a fireside chat on March 11 from 9:20 to 9:50 a.m. Eastern, along with one-on-one meetings.

Additionally, Viking management will participate in the Jefferies Biotech on the Beach Summit from March 11-12, 2025, conducting one-on-one meetings. Both events will take place in Miami, FL. A live webcast of the Leerink presentation will be available through Viking's website in the Investors & Media section, with a replay accessible post-conference.

SAN DIEGO, March 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences. 

Details of the company's participation are as follows:

• Leerink Partners Global Healthcare Conference 2025
  Details: Viking management will participate in a fireside chat and in 1-on-1 meetings
  Conference Date: March 10-12, 2025
  Fireside Chat Timing: 9:20 – 9:50 a.m. Eastern on Tuesday, March 11, 2025
  Location: Miami, FL

• Jefferies Biotech on the Beach Summit
  Details: Viking management will participate in 1-on-1 meetings
  Conference Dates: March 11-12, 2025
  Location: Miami, FL

A live webcast of the Leerink presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conference. 

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 1 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302390478.html

SOURCE Viking Therapeutics, Inc.

FAQ

When is Viking Therapeutics (VKTX) presenting at the Leerink Partners Conference 2025?

Viking Therapeutics will present a fireside chat on Tuesday, March 11, 2025, from 9:20 to 9:50 a.m. Eastern at the Leerink Partners Conference in Miami.

Which investor conferences will Viking Therapeutics (VKTX) attend in March 2025?

Viking Therapeutics will attend the Leerink Partners Global Healthcare Conference (March 10-12) and the Jefferies Biotech on the Beach Summit (March 11-12) in Miami.

How can investors watch Viking Therapeutics' (VKTX) Leerink conference presentation?

Investors can access the live webcast through Viking's website in the Investors & Media section under Webcasts, with a replay available after the conference.

What type of meetings will VKTX management conduct at these conferences?

Viking management will conduct one-on-one meetings at both conferences and participate in a fireside chat at the Leerink Partners Conference.